创业公司可享受简化药品申请注册条件 - 2017年07月13日

CHINA is overhauling its drug registration system as a part of efforts to accelerate commercial production of new medications, especially those developed by start-up firms.

It’s also seeking to broaden a trial program that allows start-up companies without their own manufacturing facilities to become the holders of new drug licenses and assume responsibility for their quality.

Before the trial program came into effect, start-up pharmaceutical companies had to build their own manufacturing capability in order to quality for a drug license.